Immuneering Atebimetinib Demonstrates Exceptional Pancreatic Cancer Survival

New pancreatic cancer drug (atebimetinib + chemo) shows "extraordinary" results: 86% overall survival (OS) at 9 months, far exceeding the 47% standard of care. Pivotal trials planned for late 2025.